In addition to its major membrane-bound form, a soluble form of PD-L1 (sPD-L1) can be found in plasma and is increased in a few cancers, where it is negatively associated with survival and the response to immunotherapy, suggesting an inhibitory effect (32, 33). The gene discussed is SPDL1; the disease is cancer.